Incyte (INCY) Other Accumulated Expenses (2017 - 2022)
Incyte (INCY) reported Other Accumulated Expenses of $57.4 million for Q2 2022, down 2.61% on a YoY basis from $58.9 million in Q2 2021, and down 22.74% quarter-over-quarter from $74.3 million in Q1 2022.
Incyte (INCY) Other Accumulated Expenses (2017 - 2022) Analysis & Trends
Incyte has reported Other Accumulated Expenses for 6 years, with the latest figure at $57.4 million in Q2 2022.
- For the quarter ending Q2 2022, Other Accumulated Expenses fell 2.61% year-over-year to $57.4 million; the trailing twelve-month figure through Jun 2022 stood at $57.4 million (down 2.61% YoY), and the FY2021 full-year result was $45.8 million, up 30.31% from the prior year.
- Other Accumulated Expenses for Q2 2022 stood at $57.4 million, down from $74.3 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $76.7 million in Q1 2021, with the low at $34.6 million in Q4 2018.
- Historically, Other Accumulated Expenses has averaged $54.9 million across 5 years, with a median of $53.5 million in 2020.
- Annual changes were most pronounced in 2020 — Other Accumulated Expenses surged 51.81% — and 2021, when it dropped 18.1%.
- Incyte's Other Accumulated Expenses stood at $34.6 million in 2018, then gained by 21.64% to $42.0 million in 2019, then decreased by 16.5% to $35.1 million in 2020, then jumped by 30.31% to $45.8 million in 2021, then increased by 25.44% to $57.4 million in 2022.
- The last three Other Accumulated Expenses figures came in at $57.4 million (Q2 2022), $74.3 million (Q1 2022), and $45.8 million (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 57.40 Mn |
| Mar 31, 2022 | 74.29 Mn |
| Dec 31, 2021 | 45.75 Mn |
| Sep 30, 2021 | 74.65 Mn |
| Jun 30, 2021 | 58.94 Mn |
| Mar 31, 2021 | 76.68 Mn |
| Dec 31, 2020 | 35.11 Mn |
| Sep 30, 2020 | 49.56 Mn |
| Jun 30, 2020 | 71.96 Mn |
| Mar 31, 2020 | 60.41 Mn |
| Dec 31, 2019 | 42.05 Mn |
| Jun 30, 2019 | 47.40 Mn |
| Mar 31, 2019 | 39.91 Mn |
| Dec 31, 2018 | 34.57 Mn |
| Dec 31, 2017 | 22.81 Mn |